JP2016533373A5 - - Google Patents

Download PDF

Info

Publication number
JP2016533373A5
JP2016533373A5 JP2016524100A JP2016524100A JP2016533373A5 JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5 JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tumor
pancreatic cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524100A
Other languages
English (en)
Japanese (ja)
Other versions
JP6525983B2 (ja
JP2016533373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/050952 external-priority patent/WO2015054781A1/en
Publication of JP2016533373A publication Critical patent/JP2016533373A/ja
Publication of JP2016533373A5 publication Critical patent/JP2016533373A5/ja
Application granted granted Critical
Publication of JP6525983B2 publication Critical patent/JP6525983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524100A 2013-10-18 2014-10-03 膵癌の治療法 Expired - Fee Related JP6525983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892887P 2013-10-18 2013-10-18
US61/892,887 2013-10-18
PCT/CA2014/050952 WO2015054781A1 (en) 2013-10-18 2014-10-03 Treatment for pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2016533373A JP2016533373A (ja) 2016-10-27
JP2016533373A5 true JP2016533373A5 (https=) 2017-11-09
JP6525983B2 JP6525983B2 (ja) 2019-06-05

Family

ID=52827497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524100A Expired - Fee Related JP6525983B2 (ja) 2013-10-18 2014-10-03 膵癌の治療法

Country Status (13)

Country Link
US (1) US9642856B2 (https=)
EP (1) EP3057593B1 (https=)
JP (1) JP6525983B2 (https=)
KR (1) KR102195494B1 (https=)
CN (1) CN105764515B (https=)
AU (1) AU2014336917B2 (https=)
CA (1) CA2927612C (https=)
EA (1) EA030089B1 (https=)
ES (1) ES2908200T3 (https=)
IL (1) IL245037B (https=)
MX (1) MX357763B (https=)
SG (1) SG11201602882VA (https=)
WO (1) WO2015054781A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークUniversity Health Network キナーゼインヒビターおよびこれを用いた癌の治療方法
JP5442906B2 (ja) 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
RS58413B1 (sr) 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
AU2018328773B2 (en) * 2017-09-08 2023-11-16 University Health Network Combination therapies for inhibition of Polo-like Kinase 4
SG11202111003UA (en) 2019-04-24 2021-11-29 Univ Health Network Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1998007695A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
AU3770000A (en) 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ/ホスファターゼ阻害剤としてのインドリノン誘導体
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
US20070167488A1 (en) 2003-12-16 2007-07-19 Leo Pharma A/S Novel therapeutic use
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
WO2008001886A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitor
WO2008152014A2 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Rsk1阻害作用を有する新規スピロインダン誘導体
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
JP5593234B2 (ja) 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク ニューロペプチドy5r(npy5r)アンタゴニストを使用して癌を治療する方法
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
JP5629752B2 (ja) * 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークUniversity Health Network キナーゼインヒビターおよびこれを用いた癌の治療方法
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Jfeスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
JP7194128B2 (ja) 2017-06-29 2022-12-21 イェンタイ クワンティシジョン ディアグノスティックス インク 固形腫瘍の診断用のバイオマーカーの絶対定量の方法および装置

Similar Documents

Publication Publication Date Title
JP2016533373A5 (https=)
Catalano et al. Gastric cancer
JP2016538344A5 (https=)
JP2019523214A5 (https=)
JP2016533366A5 (https=)
JP2015513919A5 (https=)
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
JP2013503174A5 (https=)
JP2017517520A5 (https=)
AR094849A1 (es) Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer
JP2016501221A5 (https=)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2016506413A5 (https=)
JP2017527582A5 (https=)
JP2018513155A5 (https=)
JP2019506392A5 (https=)
JP2016520057A5 (https=)
JP2017516827A5 (https=)
JP2016526021A5 (https=)
JP2013528215A5 (https=)
JP2019517507A5 (https=)
JP2016529236A5 (https=)
JP2016522188A5 (https=)
JP2020500907A5 (https=)
JP2011500841A5 (https=)